Member Blog: Regulating the Cannabis Industry for Accuracy and Integrity

Member Blog: Regulating the Cannabis Industry for Accuracy and Integrity

Regulating the Cannabis Industry for Accuracy and Integrity 

In the fast-evolving landscape of the cannabis industry, ensuring accurate testing standards is paramount to safeguarding consumer safety, maintaining regulatory compliance, and fostering fair market competition. However, a pervasive challenge known as cannabinoid inflation threatens to undermine these essential principles, posing a significant obstacle to the industry’s growth and legitimacy. 

Understanding Cannabinoid Inflation 

Cannabinoid inflation refers to the practice of cannabis testing laboratories providing inaccurately high cannabinoid concentrations in their reports, often in an attempt to attract business. This phenomenon distorts market dynamics, leading to unfair competition and jeopardizing the credibility of legitimate labs that adhere to rigorous testing standards. Contaminant deflation is a significant concern, too, as labs willing to inflate cannabinoids are also more likely to underreport the presence and/or amount of hazardous substances. 

At the heart of this issue lies a fundamental discrepancy between reported and actual cannabinoid content in cannabis products. As cannabis producers and distributors seek out labs offering higher THC values, a troubling trend is to use only labs that will inflate the value of desirable cannabinoids, such as THC. This practice, known as laboratory shopping, perpetuates the cycle of inflated results, undermining integrity and forcing accurate reporting labs out of business. 

Proposing Regulatory Solutions 

To address this pressing cannabinoid inflation challenge, Digamma Consulting, renowned experts in cannabis chemistry, presents a comprehensive set of regulatory solutions in their latest white paper, Solutions to Cannabinoid Inflation. 

Solution A: Data Analysis Reports Advocating the adoption of data analysis reports, Digamma proposes a systematic approach to analyzing testing data, providing regulators with a solid foundation for action. By leveraging data analytics, authorities can identify trends, anomalies, and potential instances of cannabinoid inflation. Such identification enables regulators to make targeted and legally justified interventions that can help to improve testing integrity. 

Solution B: Suspect Product Checks Digamma recommends implementing suspect product checks, also known as “secret shopper” programs, to detect inflated cannabinoid values. This cost-effective mechanism allows states to conduct product sampling and testing of suspected lab results by independent accredited reference laboratories that will validate reported cannabinoid content and mitigate inflated results. 

Solution C: Chemical Analysis Laboratory Audits Digamma proposes implementing in-person audits of chemical analysis laboratories to ensure testing integrity and thus directly address cannabinoid inflation. Subjecting testing facilities to rigorous scrutiny by expert auditors enables regulators to assess compliance with standards and uphold the integrity of the testing process. 

Digamma’s White Paper: Solutions to Cannabinoid Inflation 

Digamma’s white paper on regulating the cannabis industry for accuracy and integrity represents a significant step toward addressing the pervasive challenge of cannabinoid inflation. By advocating for practical, low-cost regulatory solutions, Digamma Consulting aims to empower government regulators to uphold transparency, impartiality, and legal defensibility in cannabis testing reporting and labeling. 

As the industry continues to evolve, it is imperative to prioritize consumer safety, regulatory compliance, and market fairness. Through collaborative efforts and ongoing dialogue, we can navigate the complexities of the cannabis industry and propel it toward a future characterized by integrity, transparency, and accountability. Join Digamma in the quest to build a safe, fair, and thriving cannabis industry for all.

Read the white paper here: 87910.pdf 

Author & Company Information

Marco Troiani

Marco Troiani is the founder and CEO of Digamma Consulting, a chemical analysis consulting firm servicing cannabis, hemp and environmental industries. Marco Troiani was the laboratory manager of DB Labs from its founding 2015-2016. His responsibilities included developing methods for the detection of terpenes and solvents (GC-MS), metals (ICP-MS), pesticides (GC-MS-MS), and Total Yeast and Mold, Total Aerobic Bacteria, Total Coliform Bacteria, and Salmonella spp. in cannabis and associated products, as well as hiring, training and managing lab employees. Additionally, Mr. Troiani was responsible for writing and maintaining the laboratory QAQC manual, and was responsible for personally signing each certificate of analysis released to a client. Mr. Troiani worked with representatives from the state of Maine to consult regarding the legalization of cannabis in that jurisdiction. Mr. Troiani’s previous experience includes working as a lab technician at Steep Hill under Mr. Sguera, and previously working at the Lokey Research Group in Santa Cruz, CA on synthesizing and assaying for membrane permeability a series of novel peptides derived from natural venoms. Mr Troiani’s work with analytical laboratories includes: developing new methods, validating existing methods, increasing the robustness of quality and client data generated by a laboratory, often to meet accreditation standards. Mr. Troiani’s work with extraction laboratories includes: increasing yields, purity and terpene retention of cannabis concentrates. Work with medical laboratories includes: presenting data generated by peer-reviewed publications on the safety and efficacy of cannabis as a medicine, educating doctors and clinicians on the chemical composition of cannabis, education on analysis performed on cannabis for potency and safety standards, education on the endocannabinoid system and the properties of cannabinoids in the human body. Mr. Troiani has lectured on the science of cannabis in various contexts: American Chemical Society Fall 2016, Pesticide extraction and detection in cannabis; CannMed Conference 2017, Medical benefits of terpenes in cannabis; American Chemical Society Fall 2017, Terpenes in cannabis and statistical variation between strains; Emerald Scientific Conference 2018, Linking medical benefits of terpenes to the statistical prevalence in cannabis strains; Terpenes and Testing World Conference 2018, A new intuitive terpene labeling system for cannabis; CannMed Conference 2018, Terpene enzymology and clustering in cannabis; Emerald 2019, defensible and reproducible analysis of pesticides in cannabis. Marco holds a B.Sci. in Molecular, Cellular, and Developmental Biology from UC Santa Cruz.

Empower Your Voice: Unveiling NCIA’s Updated Congressional Scorecard

Related Posts

Join the movement

NCIA is leading the cannabis industry's unified and coordinated campaign to ensure our business sector is treated fairly and has the opportunity to reach its full potential. Now - more than ever - is the time to invest in your business and the future of the industry by becoming a member.

This site uses cookies. By using this site or closing this notice, you agree to the use of cookies and our privacy policy.